US 9,809,650 B2
Anti-CD79B antibodies and immunoconjugates and methods of use
Yvonne Chen, San Mateo, CA (US); Mark Dennis, San Carlos, CA (US); David Dornan, San Mateo, CA (US); Kristi Elkins, San Francisco, CA (US); Jagath Reddy Junutula, Fremont, CA (US); Andrew Polson, San Francisco, CA (US); and Bing Zheng, Mountain View, CA (US)
Assigned to GENENTECH, INC., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Jun. 9, 2015, as Appl. No. 14/734,957.
Application 14/219,473 is a division of application No. 12/353,917, filed on Jan. 14, 2009, granted, now 8,722,857, issued on May 13, 2014.
Application 14/734,957 is a continuation of application No. 14/219,473, filed on Mar. 19, 2014.
Application 12/353,917 is a continuation of application No. PCT/US2008/070088, filed on Jul. 15, 2008.
Application PCT/US2008/070088 is a continuation of application No. 12/173,465, filed on Jul. 15, 2008, granted, now 8,088,378, issued on Jan. 3, 2012.
Claims priority of provisional application 61/054,709, filed on May 20, 2008.
Claims priority of provisional application 61/032,790, filed on Feb. 29, 2008.
Claims priority of provisional application 61/025,137, filed on Jan. 31, 2008.
Prior Publication US 2015/0314016 A1, Nov. 5, 2015
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61K 38/05 (2006.01); A61K 31/537 (2006.01); A61K 51/10 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 31/537 (2013.01); A61K 38/05 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/4863 (2013.01); A61K 47/48384 (2013.01); A61K 47/48415 (2013.01); A61K 47/48561 (2013.01); A61K 47/48715 (2013.01); A61K 51/1027 (2013.01); C07K 16/3061 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 27 Claims
 
1. An immunoconjugate comprising an anti-CD79b cysteine engineered antibody, wherein the antibody comprises a heavy chain and a light chain,
wherein the light chain comprises
(i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194);
(ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195); and
(iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196);
wherein the heavy chain comprises
(i) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202);
(ii) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203); and
(iii) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204), and
wherein the antibody comprises an engineered cysteine at position 118 of the heavy chain according to EU numbering convention, and wherein the anti-CD79b cysteine engineered antibody is covalently attached to a cytotoxic agent through the engineered cysteine.